Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Val Gebski

Showing results (211-220 of 248) with videos related to

Pageof 25
Sort By:
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Gynecologic Oncology|March 25, 2021
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trialMonika Janda, Kristy P Robledo, Val Gebski, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2020
Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK TrialPaul Keall, Doan Trang Nguyen, Ricky O'Brien, et al.
Gynecologic Oncology|May 31, 2021
Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151]Monika Janda, Kristy P Robledo, Val Gebski, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
British Journal of Cancer|December 21, 2025
High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD)Visalini Nair-Shalliker, David P Smith, Val Gebski, et al.
Respiratory Research|December 5, 2025
A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocolCarly Barton, Mariana Hoffman, Narelle S Cox, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialDavid L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
Pageof 25

Showing results (211-220 of 248) with videos related to

Sort By:
Pageof 25
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
Gynecologic Oncology|March 25, 2021
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trialMonika Janda, Kristy P Robledo, Val Gebski, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2020
Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK TrialPaul Keall, Doan Trang Nguyen, Ricky O'Brien, et al.
Gynecologic Oncology|May 31, 2021
Corrigendum to "Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial" [Gynecologic Oncology 161 (2021) 143-151]Monika Janda, Kristy P Robledo, Val Gebski, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
British Journal of Cancer|December 21, 2025
High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD)Visalini Nair-Shalliker, David P Smith, Val Gebski, et al.
Respiratory Research|December 5, 2025
A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocolCarly Barton, Mariana Hoffman, Narelle S Cox, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trialDavid L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
Pageof 25